Fresenius Kabi gets SEBI’s nod to delist shares from Indian stock market

23 Jul 2013 Evaluate

Fresenius Kabi Oncology has received approval from Securities and Exchange Board of India (SEBI) to delist its shares from the Indian stock market. As per the SEBI’s order, the healthcare firm has to complete the delisting process within three months. The market regulator also said that the company would have to take into account its pre-OFS (Offer for Sale) promoter holding of October 2012 to determine the minimum number of shares to be acquired for the delisting.

As on September 2012, Fresenius Kabi (Singapore) Pte, the parent firm held 90% stake in the company, while remaining 10% stake were with the public shareholders.

Fresenius Kabi Oncology manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×